Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug which has been approved by the U.S. Food and Drug Administration and has been prescribed to several thousands of patients in the United States, Jakafi.
As of 2014 the company was developing an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly called baricitinib. As of August 2016 31 clinical trials had been registered for baricitinib of which 24 had completed, and 4 of 6 phase 3 trials had completed.
As of 2016 epacadostat, an Indoleamine 2,3-dioxygenase *, Merck’s anti-PD-1 therapy. In 2017 the phase III KEYNOTE-252/ECHO-301 trial reported good results for epacadostat in some types of melanoma.
Novartis acquired Incyte's c-Met inhibitor capmatinib, which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.
|Traded as||NASDAQ: INCY NASDAQ-100 Component S&P 500 Component|
|Key people||Hervé Hoppenot (President and CEO, 2014)|
|Headquarters||Wilmington, Delaware, United States|
|Net income||~(US$186.5 million) (2011)|
|Total equity||~(US$227 million) (2011)|
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Biotechnology: Commercial Physical & Biological Resarch is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Incyte Corporation sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Incyte Corporation with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
|marks & spencer||Consumer Brands / Grocery||-10|
|McDonald's||Consumer Brands / Fast Food||-8|
|Tesco||Consumer Brands / Grocery||-8|
|US Airways||Travel and Hospitality / Airlines||-8|
|Amazon Prime||Consumer Brands / Entertainment||-11|
|Ziggo||Telecommunications / Other||-11|
|Golomt Bank||Financial Services / Banking||-11|
|Wells Fargo & Company||Financial Services / Banking||-12|
|NatWest Business Banking||Financial Services / Banking||-6|
|Virgin Media||Telecommunications / Cable/TV service||-6|
We have estimated the Net Promoter Score of Incyte Corporation based on the publicly available information
including the the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.